Global Tenofovir Disoproxil Fumarate Market Overview
As per MRFR analysis, the Tenofovir Disoproxil Fumarate Market Size was estimated at 1.83 (USD Billion) in 2022.
The Tenofovir Disoproxil Fumarate Industry is expected to grow from 1.95(USD Billion) in 2023 to 3.41 (USD Billion) by 2032. The Tenofovir Disoproxil Fumarate Market CAGR (growth rate) is expected to be around 6.41% during the forecast period (2024 - 2032).
Key Tenofovir Disoproxil Fumarate Market Trends Highlighted
Key market drivers for tenofovir disoproxil fumarate include the increasing prevalence of HIV/AIDS, the growing adoption of pre-exposure prophylaxis (PrEP) for HIV prevention, and the rising demand for generic antiretroviral drugs. Opportunities to be explored or captured in the tenofovir disoproxil fumarate market include the development of new formulations and combinations of tenofovir disoproxil fumarate, the expansion into new markets, and the potential for use in the treatment of other viral infections.
Recent trends in the tenofovir disoproxil fumarate market include the increasing use of PrEP for HIV prevention, the growing demand for generic antiretroviral drugs, and the development of new formulations and combinations of tenofovir disoproxil fumarate. These trends are expected to continue in the coming years, driving growth in the tenofovir disoproxil fumarate market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Tenofovir Disoproxil Fumarate Market Drivers
Rising Prevalence of HIV/AIDS
The major driver for the Tenofovir Disoproxil Fumarate Market Industry is the increasing prevalence of HIV/AIDS. Tenofovir Disoproxil Fumarate is a drug that is used to prevent and treat HIV/AIDS. Therefore, with the increasing prevalence of these diseases, the market is expected to grow. In 2021, approximately 38.4 million people are living with HIV worldwide. Moreover, in 2020 it is estimated that about 1.5 million people became newly infected with HIV and 680,000 people died from AIDS related illnesses.
The prevalence of HIV/AIDS is expected to increase even in the coming years. This will drive the demand for Tenofovir Disoproxil Fumarate, thus being a major driver for the Tenofovir Disoproxil Fumarate Market Industry.
Increasing Government Initiatives
The Tenofovir Disoproxil Fumarate Market Industry is also driven by government-sponsored initiatives to control HIV/AIDS. Governments across the world are enacting programs and policies to prevent the spread and treat HIV/AIDS. This includes making Tenofovir Disoproxil Fumarate more available at an affordable cost. In 2021, for example, the U.S. government announced a new initiative to invest $250 million in the next five years to expand access to HIV prevention and treat services in the U.S.
This will include making Tenofovir Disoproxil Fumarate more accessible. Similar programs are also being pursued in other countries which will increase the market size.
Growing Awareness of PrEP
Increasing awareness of pre-exposure prophylaxis (PrEP) is also contributing to the growth of the Tenofovir Disoproxil Fumarate Market Industry. PrEP is a medication regimen that can be taken by HIV-negative individuals to prevent HIV infection. Tenofovir Disoproxil Fumarate is one of the most commonly used medications for PrEP, and the growing awareness of PrEP is expected to drive demand for Tenofovir Disoproxil Fumarate and contribute to the growth of the Tenofovir Disoproxil Fumarate Market Industry.
Tenofovir Disoproxil Fumarate Market Segment Insights
Tenofovir Disoproxil Fumarate Market Route of Administration Insights
The Tenofovir Disoproxil Fumarate Market is divided into the Oral and Intravenous segments on the Route of Administration. The Oral will retain its dominant position with an 86.5% market share in 2023. Its dominance is driven by the ease of administration, patient convenience, and cost-effectiveness compared with the Intravenous segment. On the other hand, IV administration will maintain its marginal market share with a value of 13.5% in 2023. This segment is used in an institutional setting and for patients who cannot be administered the oral form of the drug.
Oral has a slightly faster growth rate at 6.1% and an estimated value of 2.68 billion USD in 2032. Meanwhile, IV administration will register an 5.8% value at 0.73 billion USD over the same period. The increasing prevalence of HIV/AIDS and the demand for effective antiretroviral therapy is a critical driver of the Tenofovir Disoproxil Fumarate Market. Second, the growing knowledge of the potential of this therapy to prevent the spread of HIV and manage chronic hepatitis B will contribute to the market’s expected growth. Finally, the market is forecast to register substantial gains, mainly based on the fact that a growing number of persons who have been exposed to the risk of contracting HIV will rely on daily Tenofovir Disoproxil Fumarate as a pre-exposure prophylaxis medication.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Tenofovir Disoproxil Fumarate Market Indication Insights
The Tenofovir Disoproxil Fumarate Market is segmented based on indication into HIV Pre-Exposure Prophylaxis (PrEP), HIV Treatment, and Hepatitis B Virus Infection. The HIV Treatment segment is expected to hold the largest market share of around 55.3% in 2023 due to the increasing prevalence of HIV worldwide. The HIV Pre-Exposure Prophylaxis (PrEP) segment is anticipated to grow at the highest CAGR of 7.6% during the forecast period owing to the growing awareness about PrEP as an effective method to prevent HIV infection. The Hepatitis B Virus Infection segment is projected to account for a market share of approximately 18.5% in 2023, primarily driven by the rising incidence of hepatitis B virus infection in developing countries.
Tenofovir Disoproxil Fumarate Market Patient Population Insights
The Tenofovir Disoproxil Fumarate Market is segmented based on patient population into HIV-positive adults, HIV-positive adolescents, and HIV-exposed newborns and infants. Among these segments, the HIV-positive adults segment accounted for the largest share of the market in 2023, and is expected to continue to dominate the market over the forecast period. The high prevalence of HIV among adults, coupled with the increasing adoption of Tenofovir Disoproxil Fumarate for the treatment of HIV, is driving the growth of this segment. The HIV-positive adolescents segment is also expected to witness significant growth over the forecast period.
The increasing awareness about HIV prevention and treatment among adolescents, as well as the availability of affordable Tenofovir Disoproxil Fumarate formulations, are contributing to the growth of this segment. The HIV-exposed newborns and infants segment is expected to grow at a steady pace over the forecast period. The increasing number of HIV-infected pregnant women, coupled with the need for effective prevention of mother-to-child transmission of HIV, is driving the growth of this segment.
Tenofovir Disoproxil Fumarate Market Dose Insights
The Tenofovir Disoproxil Fumarate Market is segmented based on dose into Once-Daily and Twice-Daily. The Once-Daily segment is expected to hold a significant market share due to the convenience and adherence benefits associated with once-daily dosing regimens. The Twice-Daily segment, however, is expected to witness steady growth owing to the availability of generic formulations and the lower cost associated with twice-daily dosing. In 2023, the Once-Daily segment accounted for a larger share of the Tenofovir Disoproxil Fumarate Market revenue, and this trend is expected to continue in the coming years.
The growth of the Once-Daily segment can be attributed to the increasing preference for convenient and patient-friendly treatment options. Additionally, the availability of once-daily formulations has simplified treatment regimens and improved patient compliance, leading to better therapeutic outcomes.
Tenofovir Disoproxil Fumarate Market Formulation Insights
The Tenofovir Disoproxil Fumarate Market is segmented based on formulation into tablets and oral solution. The tablets segment is expected to hold a larger market share due to the ease of administration and widespread availability. The oral solution segment is expected to grow at a faster rate due to the increasing preference for liquid formulations, especially among pediatric patients. In 2023, the tablets segment held 65% of the market revenue, while the oral solution segment held 35% of the market revenue. By 2032, it is estimated that the tablets segment will hold 60% of the market revenue, while the oral solution segment will hold 40% of the market revenue.
The growth of the oral solution segment is attributed to the development of new formulations that offer improved taste and palatability, making them more acceptable to patients.
Tenofovir Disoproxil Fumarate Market Regional Insights
The regional segmentation of the Tenofovir Disoproxil Fumarate Market presents diverse growth opportunities across key geographic regions. North America holds a significant market share, driven by factors such as high healthcare expenditure, advanced research and development, and a large patient population. Europe follows closely, with a well-established healthcare infrastructure and a growing demand for Tenofovir Disoproxil Fumarate for the treatment of HIV and hepatitis B. The Asia-Pacific region is poised for substantial growth, fueled by rising healthcare awareness, increasing disposable income, and a large population base.
South America and the Middle East and Africa (MEA) regions are also expected to contribute to the overall market growth, with increasing investments in healthcare infrastructure and government initiatives aimed at improving access to essential medicines. The Tenofovir Disoproxil Fumarate Market is expected to continue expanding in the coming years, driven by factors such as rising prevalence of HIV and hepatitis B, increasing healthcare expenditure, and the development of new formulations and combination therapies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Tenofovir Disoproxil Fumarate Market Key Players And Competitive Insights:
Major Tenofovir Disoproxil Fumarate Market companies in the market are focusing on expanding their products and services. Moreover, the Tenofovir Disoproxil Fumarate Market companies are focusing on the launch of new products and increasing investments in research and development. In addition to the aforementioned strategies, the leading players in the Tenofovir Disoproxil Fumarate Market industry are investing in expanding geographic presence by setting up new manufacture and distribution centers. Tenofovir Disoproxil Fumarate Market development is driven by the increasing prevalence of HIV/AIDS and other sexually transmitted infections (STIs) and the growing demand for cheap and reliable services and products. The Tenofovir Disoproxil Fumarate Markets are driven by the development of several large multinational pharmaceutical companies alongside small companies offering generic prescription and over the counter Tenofovir Disoproxil Fumarate Market products. The Tenofovir Disoproxil Fumarate Market companies include Gilead Sciences, Inc., Cipla, Mylan N.V. and Sun Pharmaceutical Industries Limited.
Gilead Sciences, Inc. is the leading company in the Tenofovir Disoproxil Fumarate Market industry. The company offers a large number of drugs used in the treatment of human immunodeficiency virus and acquired immunodeficiency virus. The company is widely spread globally, and markets its products in over 100 countries. The company has a strong drug research and development component, and therefore, always invests in research of new and efficient treatment of HIV/AIDS.
Mylan N.V. is a leading pharmaceutical company that deals with the manufacture of generic and specialty pharmaceuticals. The company has operations in over 165 countries. The company is known for the production of affordable prescription and over the counter Tenofovir Disoproxil Fumarate Market products.
Key Companies in the Tenofovir Disoproxil Fumarate Market Include:
- Cadila Healthcare
- Cipla Limited
- Cipla
- Zydus Cladenas
- Mylan Laboratories
- Torrent Pharmaceuticals
- ViiV Healthcare
- Hetero Labs
- Lupin
- Gilead Sciences
- Teva Pharmaceutical Industries
- Aurobindone Pharmaceutcials
- Strides Pharma Science Limited
- Glenmark Pharmaceuticals
- Sun Pharmaceutcials
Tenofovir Disoproxil Fumarate Industry Developments
The Tenofovir Disoproxil Fumarate market size was valued at USD 1.95 billion in 2023 and is projected to reach USD 3.41 billion by 2032, exhibiting a CAGR of 6.41% during the forecast period. The market growth is primarily driven by the increasing prevalence of HIV/AIDS, the rising adoption of PrEP for HIV prevention, and the growing awareness about the benefits of Tenofovir Disoproxil Fumarate in treating chronic hepatitis B.
Key recent developments include the WHO's recommendation of Tenofovir Disoproxil Fumarate as the preferred first-line treatment for HIV and the launch of generic versions of the drug, which is expected to further drive market growth in the coming years.
Tenofovir Disoproxil Fumarate Market Segmentation Insights
Tenofovir Disoproxil Fumarate Market Route of Administration Outlook
Tenofovir Disoproxil Fumarate Market Indication Outlook
- HIV Pre-Exposure Prophylaxis (PrEP)
- HIV Treatment
- Hepatitis B Virus Infection
Tenofovir Disoproxil Fumarate Market Patient Population Outlook
- HIV-Positive Adults
- HIV-Positive Adolescents
- HIV-Exposed Newborns and Infants
Tenofovir Disoproxil Fumarate Market Dose Outlook
Tenofovir Disoproxil Fumarate Market Formulation Outlook
Tenofovir Disoproxil Fumarate Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
1.83(USD Billion) |
| Market Size 2023 |
1.95(USD Billion) |
| Market Size 2032 |
3.41(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
6.41% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Cadila Healthcare, Cipla Limited, Cipla, Zydus Cladenas, Mylan Laboratories, Torrent Pharmaceuticals, ViiV Healthcare, Hetero Labs, Lupin, Gilead Sciences, Teva Pharmaceutical Industries, Aurobindone Pharmaceutcials, Strides Pharma Science Limited, Glenmark Pharmaceuticals, Sun Pharmaceutcials |
| Segments Covered |
Route of Administration, Indication, Patient Population, Dose, Formulation, Regional |
| Key Market Opportunities |
Rise in HIVAIDS Government initiatives Emerging markets Technological advancements Growing awareness |
| Key Market Dynamics |
Rising HIVAIDS Prevalence Increasing Demand for PreExposure Prophylaxis Growing Awareness about HIV Prevention |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Tenofovir Disoproxil Fumarate market size is expected to reach USD 3.41 billion by 2032, exhibiting a CAGR of 6.41% during the forecast period (2024-2032).
Rising prevalence of HIV and hepatitis B virus infections, increasing adoption of pre-exposure prophylaxis (PrEP) for HIV prevention, and growing awareness about the benefits of Tenofovir Disoproxil Fumarate are the primary factors driving the market growth.
North America is anticipated to account for the largest market share due to the high prevalence of HIV and hepatitis B infections, well-established healthcare infrastructure, and favorable reimbursement policies.
The HIV treatment segment is projected to dominate the market, accounting for a significant share, owing to the widespread use of Tenofovir Disoproxil Fumarate as a first-line treatment for HIV infection.
Gilead Sciences, Inc., Cipla Limited, Mylan N.V., Hetero Labs Limited, and Teva Pharmaceutical Industries Ltd. are the prominent players in the Tenofovir Disoproxil Fumarate market.
Technological advancements, such as the development of long-acting injectables and combination therapies, are expected to shape the future of the Tenofovir Disoproxil Fumarate market.
The COVID-19 pandemic has had a limited impact on the Tenofovir Disoproxil Fumarate market. While there was a temporary disruption in supply chains, the demand for the drug remained relatively stable due to its essential role in HIV and hepatitis B treatment.
The emergence of drug resistance, stringent regulatory requirements, and patent expiries are some of the challenges faced by the Tenofovir Disoproxil Fumarate market.
The future of the Tenofovir Disoproxil Fumarate market appears promising, driven by the increasing prevalence of HIV and hepatitis B infections, ongoing research and development, and expanding access to healthcare in developing regions.
The market presents growth opportunities in emerging markets, the development of new formulations, and collaborations between pharmaceutical companies and healthcare providers to improve patient outcomes.
